Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children
Language English Country United States Media print
Document type Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't
PubMed
31805182
PubMed Central
PMC7019192
DOI
10.1182/blood.2019000998
PII: S0006-4971(20)62251-0
Knihovny.cz E-resources
- MeSH
- Time Factors MeSH
- Dabigatran adverse effects pharmacokinetics therapeutic use MeSH
- Child MeSH
- Kaplan-Meier Estimate MeSH
- Infant MeSH
- Humans MeSH
- Adolescent MeSH
- Follow-Up Studies MeSH
- Child, Preschool MeSH
- Risk Factors MeSH
- Secondary Prevention * MeSH
- Endpoint Determination MeSH
- Venous Thromboembolism drug therapy prevention & control MeSH
- Check Tag
- Child MeSH
- Infant MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial, Phase III MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Dabigatran MeSH
This open-label, single-arm, prospective cohort trial is the first phase 3 safety study to describe outcomes in children treated with dabigatran etexilate for secondary venous thromboembolism (VTE) prevention. Eligible children aged 12 to <18 years (age stratum 1), 2 to <12 years (stratum 2), and >3 months to <2 years (stratum 3) had an objectively confirmed diagnosis of VTE treated with standard of care (SOC) for ≥3 months, or had completed dabigatran or SOC treatment in the DIVERSITY trial (NCT01895777) and had an unresolved clinical thrombosis risk factor requiring further anticoagulation. Children received dabigatran for up to 12 months, or less if the identified VTE clinical risk factor resolved. Primary end points included VTE recurrence, bleeding events, and mortality at 6 and 12 months. Overall, 203 children received dabigatran, with median exposure being 36.3 weeks (range, 0-57 weeks); 171 of 203 (84.2%) and 32 of 203 (15.8%) took capsules and pellets, respectively. Overall, 2 of 203 children (1.0%) experienced on-treatment VTE recurrence, and 3 of 203 (1.5%) experienced major bleeding events, with 2 (1.0%) reporting clinically relevant nonmajor bleeding events, and 37 (18.2%) minor bleeding events. There were no on-treatment deaths. On-treatment postthrombotic syndrome was reported for 2 of 162 children (1.2%) who had deep vein thrombosis or central-line thrombosis as their most recent VTE. Pharmacokinetic/pharmacodynamic relationships of dabigatran were similar to those in adult VTE patients. In summary, dabigatran showed a favorable safety profile for secondary VTE prevention in children aged from >3 months to <18 years with persistent VTE risk factor(s). This trial was registered at www.clinicaltrials.gov as #NCT02197416.
Biostatistics and Data Sciences Boehringer Ingelheim Pharmaceuticals Inc Ridgefield CT
Boehringer Ingelheim Singapore Pte Ltd Singapore
Children's Hospital of Eastern Ontario University of Ottawa Ottawa ON Canada
Department of Clinical Development Boehringer Ingelheim RCV GmbH and Co KG Vienna Austria
Department of Pediatrics University of Alberta Edmonton AB Canada
Faculty of Medicine Mannheim of the University of Heidelberg Mannheim Germany
Faculty of Medicine University of Ostrava Ostrava Czech Republic
Hematology Department University Children's Hospital Zürich Switzerland
Masaryk University Brno Czech Republic
Pediatric Hematology Department Municipal Children's Hospital Morozovskaya Moscow Russian Federation
Pediatric Hematology Department University Hospital Brno Brno Czech Republic
Pediatric Hematology Oncology Department Pediatric Hospital Bambino Gesù Rome Italy
Pediatric Hematology Oncology Department University Hospital Ostrava Ostrava Czech Republic
Pediatric Hospital Republic of Tatarstan Kazan Medical University Kazan Russian Federation
Royal Hospital for Children Glasgow Scotland United Kingdom
See more in PubMed
Andrew M, David M, Adams M, et al. . Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood. 1994;83(5):1251-1257. PubMed
Kenet G, Kirkham F, Niederstadt T, et al. ; European Thromboses Study Group . Risk factors for recurrent venous thromboembolism in the European collaborative paediatric database on cerebral venous thrombosis: a multicentre cohort study. Lancet Neurol. 2007;6(7):595-603. PubMed PMC
Manco-Johnson MJ. How I treat venous thrombosis in children. Blood. 2006;107(1):21-29. PubMed PMC
Nowak-Göttl U, Junker R, Kreuz W, et al. ; Childhood Thrombophilia Study Group . Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood. 2001;97(4):858-862. PubMed
Monagle P, Chan AKC, Goldenberg NA, et al. . Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(suppl 2):e737S-e801S. PubMed PMC
Monagle P, Cuello CA, Augustine C, et al. . American Society of Hematology 2018 guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv. 2018;2(22):3292-3316. PubMed PMC
Chan AK, Monagle P. Updates in thrombosis in pediatrics: where are we after 20 years? Hematology Am Soc Hematol Educ Program. 2012;2012:439-443. PubMed
Polikoff LA, Faustino EVS. Venous thromboembolism in critically ill children. Curr Opin Pediatr. 2014;26(3):286-291. PubMed PMC
Massicotte MP, Sofronas M, deVeber G. Difficulties in performing clinical trials of antithrombotic therapy in neonates and children. Thromb Res. 2006;118(1):153-163. PubMed
US Food and Drug Administration Guidance document: pediatric information incorporated into human prescription drug and biological products labeling good review practice. www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm341394.pdf. Accessed 23 December 2019.
European Medicines Agency Clinical investigation of medicinal products in the paediatric population: note for guidance on clinical investigation of medicinal products in the paediatric population (CPMP/ICH/2711/99). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002926.pdf. Accessed 23 December 2019.
Schulman S, Kakkar AK, Goldhaber SZ, et al. ; RE-COVER II Trial Investigators . Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129(7):764-772. PubMed
Schulman S, Kearon C, Kakkar AK, et al. ; RE-COVER Study Group . Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-2352. PubMed
Schulman S, Kearon C, Kakkar AK, et al. ; RE-SONATE Trial Investigators . Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709-718. PubMed
Halton JM, Lehr T, Cronin L, et al. . Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents. An open-label phase IIa study. Thromb Haemost. 2016;116(3):461-471. PubMed
Halton JML, Albisetti M, Biss B, et al. . Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability. J Thromb Haemost. 2017;15(11):2147-2157. PubMed
Halton JML, Picard AC, Harper R, et al. . Pharmacokinetics, pharmacodynamics, safety and tolerability of dabigatran etexilate oral liquid formulation in infants with venous thromboembolism. Thromb Haemost. 2017;117(11):2168-2175. PubMed
Luciani M, Albisetti M, Biss B, et al. . Phase 3, single-arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: rationale and design. Res Pract Thromb Haemost. 2018;2(3):580-590. PubMed PMC
Hayton WL. Maturation and growth of renal function: dosing renally cleared drugs in children. AAPS PharmSci. 2000;2(1):E3. PubMed PMC
Mitchell LG, Goldenberg NA, Male C, Kenet G, Monagle P, Nowak-Göttl U; Perinatal and Paediatric Haemostasis Subcommittee of the SSC of the ISTH . Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in children. J Thromb Haemost. 2011;9(9):1856-1858. PubMed
Goldenberg NA, Donadini MP, Kahn SR, et al. . Post-thrombotic syndrome in children: a systematic review of frequency of occurrence, validity of outcome measures, and prognostic factors. Haematologica. 2010;95(11):1952-1959. PubMed PMC
Soosainathan A, Moore HM, Gohel MS, Davies AH. Scoring systems for the post-thrombotic syndrome. J Vasc Surg. 2013;57(1):254-261. PubMed
Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47(5):285-295. PubMed
Albisetti M, Brandão L, Bomgaars L, et al. . Efficacy and safety of dabigatran etexilate for treatment of venous thromboembolism in paediatric patients - results of the DIVERSITY trial [abstract]. Res Pract Thromb Haemost. 2019;03(suppl 1):139-140. Abstract OC 57.3.
Brüwer G, Limperger V, Kenet G, et al. . Impact of high risk thrombophilia status on recurrence among children and adults with VTE: an observational multicenter cohort study. Blood Cells Mol Dis. 2016;62:24-31. PubMed
Limperger V, Kenet G, Goldenberg NA, et al. . Impact of high-risk thrombophilia status on recurrence among children with a first non-central-venous-catheter-associated VTE: an observational multicentre cohort study. Br J Haematol. 2016;175(1):133-140. PubMed
Avčin T, Cimaz R, Silverman ED, et al. . Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics. 2008;122(5):e1100-e1107. PubMed
Berkun Y, Padeh S, Barash J, et al. . Antiphospholipid syndrome and recurrent thrombosis in children. Arthritis Rheum. 2006;55(6):850-855. PubMed
Pengo V, Denas G, Zoppellaro G, et al. . Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132(13):1365-1371. PubMed
Goldhaber SZ, Eriksson H, Kakkar A, et al. . Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: findings from RE-COVER®, RE-COVERTM II, and RE-MEDYTM. Vasc Med. 2016;21(6):506-514. PubMed
Massicotte P, Julian JA, Gent M, et al. ; REVIVE Study Group . An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res. 2003;109(2-3):85-92. PubMed
Bidlingmaier C, Kenet G, Kurnik K, et al. . Safety and efficacy of low molecular weight heparins in children: a systematic review of the literature and meta-analysis of single-arm studies. Semin Thromb Hemost. 2011;37(7):814-825. PubMed
Musgrave KM, Webber K, Murphy P, Avery P, Biss TT. Evaluation of the age-dependent dosing recommendations for the administration of daily tinzaparin in children with thrombosis. J Thromb Haemost. 2017;15(12):2361-2366. PubMed
Goldenberg NA, Brandão L, Journeycake J, et al. ; Perinatal and Paediatric Haemostasis Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis . Definition of post-thrombotic syndrome following lower extremity deep venous thrombosis and standardization of outcome measurement in pediatric clinical investigations. J Thromb Haemost. 2012;10(3):477-480. PubMed
Avila ML, Duan L, Cipolla A, et al. . Postthrombotic syndrome following upper extremity deep vein thrombosis in children. Blood. 2014;124(7):1166-1173. PubMed
Avila ML, Pullenayegum E, Williams S, Yue N, Krol P, Brandão LR. Postthrombotic syndrome and other outcomes of lower extremity deep vein thrombosis in children. Blood. 2016;128(14):1862-1869. PubMed
Cheung YW, Middeldorp S, Prins MH, et al. ; Einstein PTS Investigators Group . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thromb Haemost. 2016;116(4):733-738. PubMed
Utne KK, Dahm A, Wik HS, Jelsness-Jorgensen LP, Sandset PM, Ghanima W Rivaroxaban reduces the rate of post-thrombosis syndrome after DVT – a cross-sectional study comparing rivaroxaban to warfarin. J Thromb Haemost. 2017;1:1-15. Abstract OC 60.12.
Agnelli G, Buller HR, Cohen A, et al. ; AMPLIFY Investigators . Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808. PubMed
Agnelli G, Buller HR, Cohen A, et al. ; AMPLIFY-EXT Investigators . Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699-708. PubMed
Bauersachs R, Berkowitz SD, Brenner B, et al. ; EINSTEIN Investigators . Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510. PubMed
Maas H, Gropper S, Huang F, et al. . Anticoagulant effects of dabigatran in paediatric patients compared with adults: combined data from three paediatric clinical trials. Thromb Haemost. 2018;118(9):1625-1636. PubMed PMC
ClinicalTrials.gov
NCT02197416
